Exhibit 99.1

PDL BioPharma, Inc.

SPC Status Report

Country	Drug	Underlying Patent No.	SPC App. No.
Austria	HERCEPTIN® (Trastuzumab)	E133452	SZ36/2000
Belgium	HERCEPTIN® (Trastuzumab)	EP0451216	2000C/026
Germany	HERCEPTIN® (Trastuzumab)	68925536.5	10075038.9
Denmark	HERCEPTIN® (Trastuzumab)	PR174317	CA 2003 00007
Spain	HERCEPTIN® (Trastuzumab)	2081974T3	C200000026
Finland	HERCEPTIN® (Trastuzumab)	FI108797	L2002 0008
France	HERCEPTIN® (Trastuzumab)	EP0451216	00C0035
Great Britain	HERCEPTIN® (Trastuzumab)	GB0451216	SPC/GB00/032
Greece	HERCEPTIN® (Trastuzumab)	1001050	20000800025
Ireland	HERCEPTIN® (Trastuzumab)	82755	2003/006
Italy	HERCEPTIN® (Trastuzumab)	EP0451216	UB2000CCP708
Luxembourg	HERCEPTIN® (Trastuzumab)	EP0451216	90676
Netherlands	HERCEPTIN® (Trastuzumab)	EP0451216	300023
Norway	HERCEPTIN® (Trastuzumab)	310473	SPC/NO2001024
Portugal	HERCEPTIN® (Trastuzumab)	PT 92758	79
Sweden	HERCEPTIN® (Trastuzumab)	SE0451216	0090024-1
Austria	XOLAIR® (Omalizumab)	E133452	SZ42/2005
Belgium	XOLAIR® (Omalizumab)	EP0451216	2005C/038
Switzerland	XOLAIR® (Omalizumab)	EP0451216	C00451216/04
Germany	XOLAIR® (Omalizumab)	68925536.5	122005000057.40
Denmark	XOLAIR® (Omalizumab)	PR174317	CA 2005 00051
Spain	XOLAIR® (Omalizumab)	2081974T3	C200500046
Finland	XOLAIR® (Omalizumab)	FI108797	L20050028
France	XOLAIR® (Omalizumab)	EP0451216	05C0046
Great Britain	XOLAIR® (Omalizumab)	GB0451216	SPC/GB05/052
Hungary	XOLAIR® (Omalizumab)	211174	S0500022
Ireland	XOLAIR® (Omalizumab)	82755	2005/031
Italy	XOLAIR® (Omalizumab)	EP0451216	UB2006CCP903
Luxembourg	XOLAIR® (Omalizumab)	EP0451216	91208
Netherlands	XOLAIR® (Omalizumab)	EP0451216	300213
Norway	XOLAIR® (Omalizumab)	310473	SPC/NO2005026
Portugal	XOLAIR® (Omalizumab)	PT 92758	212
Sweden	XOLAIR® (Omalizumab)	SE0451216	0590038-6
Slovenia	XOLAIR® (Omalizumab)	SI 8912489	C-200640004
Austria	AVASTIN® (Bevacizumab)	E133452	SZ 6/2005
Belgium	AVASTIN® (Bevacizumab)	EP0451216	2005C/004
Switzerland	AVASTIN® (Bevacizumab)	EP0451216	C00451216/03
Germany	AVASTIN® (Bevacizumab)	68925536.5	12 2005 000 007.8

1

PDL BioPharma, Inc.

SPC Status Report

Country Drug Underlying Patent No. SPC App. No.

Denmark	AVASTIN® (Bevacizumab)	PR174317	CA 2005 00006
Spain	AVASTIN® (Bevacizumab)	2081974T3	C200500004
Finland	AVASTIN® (Bevacizumab)	FI108797	L20050004
France	AVASTIN® (Bevacizumab)	EP0451216	05C0004
Great Britain	AVASTIN® (Bevacizumab)	GB0451216	SPC/GB05/009
Hungary	AVASTIN® (Bevacizumab)	211174	S0500005
Ireland	AVASTIN® (Bevacizumab)	82755	2005/007
Italy	AVASTIN® (Bevacizumab)	EP0451216	CU-B2005CCP865
Luxembourg	AVASTIN® (Bevacizumab)	EP0451216	91 139
Netherlands	AVASTIN® (Bevacizumab)	EP0451216	300173
Norway	AVASTIN® (Bevacizumab)	310473	SPC/NO2005005
Portugal	AVASTIN® (Bevacizumab)	PT 92758	188
Sweden	AVASTIN® (Bevacizumab)	SE0451216	0590004-8
Slovenia	AVASTIN® (Bevacizumab)	SI 8912489	C-200540007
Austria	TYSABRI® (natalizumab)	E133452	SZ26/2006
Belgium	TYSABRI® (natalizumab)	EP0451216	2006C/024
Germany	TYSABRI® (natalizumab)	68925536.5	122006000036.4
Denmark	TYSABRI® (natalizumab)	PR174317	CA 200600022
Spain	TYSABRI® (natalizumab)	2081974T3	C200600026
Finland	TYSABRI® (natalizumab)	FI108797	L20060010
France	TYSABRI® (natalizumab)	EP0451216	06C0028
Great Britain	TYSABRI® (natalizumab)	GB0451216	SPC/GB/06/027
Hungary	TYSABRI® (natalizumab)	211174	S0600007
Ireland	TYSABRI® (natalizumab)	82755	2006/027
Italy	TYSABRI® (natalizumab)	EP0451216	C-UB2006CCP929
Luxembourg	TYSABRI® (natalizumab)	EP0451216	91272
Netherlands	TYSABRI® (natalizumab)	EP0451216	300239
Norway	TYSABRI® (natalizumab)	310473	SPC/NO2006009
Portugal	TYSABRI® (natalizumab)	PT 92758	235
Sweden	TYSABRI® (natalizumab)	SE0451216	0690023-7
Slovenia	TYSABRI® (natalizumab)	SI 8912489	C-200640013
Switzerland	TYSABRI® (natalizumab)	EP0451216	C00451216/05
Austria	LUCENTIS® (Ranibizumab)	E133452	SZ36/2007
Belgium	LUCENTIS® (Ranibizumab)	EP0451216	2007C/030
Bulgaria	LUCENTIS® (Ranibizumab)	BG61095	07/041
Germany	LUCENTIS® (Ranibizumab)	68925536.5	122007000037.5
Denmark	LUCENTIS® (Ranibizumab)	PR174317	CA 2007 00029
Spain	LUCENTIS® (Ranibizumab)	2081974T3	C200700020

2

PDL BioPharma, Inc.

SPC Status Report

Country Drug Underlying Patent No. SPC App. No.

Finland	LUCENTIS® (Ranibizumab)	FI108797	L20070013
France	LUCENTIS® (Ranibizumab)	EP0451216	07C0029
Great Britain	LUCENTIS® (Ranibizumab)	GB0451216	SPC/GB07/033
Hungary	LUCENTIS® (Ranibizumab)	211174	S070003
Ireland	LUCENTIS® (Ranibizumab)	82755	2007/019
Italy	LUCENTIS® (Ranibizumab)	EP0451216	UB2007CCP969
Luxembourg	LUCENTIS® (Ranibizumab)	EP0451216	91333
Netherlands	LUCENTIS® (Ranibizumab)	EP0451216	300279
Norway	LUCENTIS® (Ranibizumab)	310473	SPC/NO2007006
Portugal	LUCENTIS® (Ranibizumab)	PT 92758	269
Sweden	LUCENTIS® (Ranibizumab)	SE0451216	0790030-1
Slovenia	LUCENTIS® (Ranibizumab)	SI 8912489	C-200740008

3